Our dual focus on scaling human immunology while also replacing animal models will transform immunotherapy discovery and treat previously untreatable diseases.
Turning drug makers into optimists
95% of drugs never see the light of day.
By shifting immunotherapy discovery into organoids we will be discovering drugs in humans, radically raising the chance that a drug makes it to patients.
Faster, cheaper, and better drugs
Shaving $2B and 9 years of each drug program means faster time-to-market at lower cost for pharma.
Using human data on day one means more effective therapies with lower side-effects become the norm.
A healthier world for everyone
Faster, more efficient drug pipelines means more therapies for more diseases make it to people.
Diverse organoids mean that therapies reach every population in the world faster.
What We Do
We actively work with the world’s biggest pharma and biotech companies. With one technology we solve many problems: It is the only technology that delivers true human immune response outside of a patient.
Trial-in-a-Dish
Predict drug safety in a diverse representation of the population to create better medications
Disease Modeling
Create realistic, patient matched models of disease that surpasses everything that exists today
Target Discovery
Use healthy and disease organoids to identify novel causes and targets for new drug programs
About Us
The immune system is the master regulator of health and disease. Medicines that target the immune system – called immunotherapies – are the most effective drugs we’ve ever developed, whether it’s a new cancer therapy that rapidly kills tumors or a vaccine that prevents us from getting sick in the first place. Therefore, immunotherapies will be the future of medicine as they continue to be developed and deployed.
Join us on our journey as we create new tools to push the boundaries of what is possible.